Chakrit Hirunpetcharat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chakrit Hirunpetcharat has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
A.M. Krieg
Veterans Affairs Medical Centre, Iowa City, IA 522436, USA
1 shared publicationD.G. Heppner
Department of Immunology, Division of Communicable Diseases and Immunology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
1 shared publicationD.S. Walsh
Department of Immunology and Medicine, US Armed Forces Research Institute of Medical Science, Rajvithi Road, Bangkok 10400, Thailand
1 shared publicationJ. Wipasa
The Queensland Institute of Medical Research, Brisbane 4029, Australia
1 shared publicationLeera Kittigul
Department of Microbiology, Faculty of Public Health,1 Department of Microbiology and Immunology, Faculty of Tropical Medicine,2 Department of Parasitology, Faculty of Public Health, Mahidol University, Bangkok, Thailand,3 Department of Immunology and Medicine, U.S. Armed Forces Research Institute of Medical Science, Bangkok, Thailand4
1 shared publicationM.F. Good
The Queensland Institute of Medical Research, Brisbane 4029, Australia
1 shared publication
Latest Publications
- 1 April 2007
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (4) , 342-347
Long-Lasting Protective Immune Response to the 19-Kilodalton Carboxy-Terminal Fragment ofPlasmodium yoeliiMerozoite Surface Protein 1 in Mice
Merozoite surface protein 1 (MSP1) is the major protein on the surface of the plasmodial merozoite, and its carboxy terminus, the 19-kDa fragment (MSP119), is highly conserved and effective in induction of a protective immune response against malaria parasite infection in mice and monkeys. However, the duration of the immune response has not been elucidated. As such, we immunized BALB/c mice with a standard four-dose injection of recombinantPlasmodium yoeliiMSP119formulated with Montanide ISA51 and CpG oligodeoxynucleotide (ODN) and monitored the MSP119-specific antibody levels for up to 12 months. The antibody titers persisted constantly over the period of time without significant waning, in contrast to the antibody levels induced by immunization with Freund's adjuvant, where the antibody levels gradually declined to significantly lower levels 12 months after immunization. Investigation of immunoglobulin G (IgG) subclass longevity revealed that only the IgG1 antibody level (Th2 type-driven response) decreased significantly by 6 months, while the IgG2a antibody level (Th1 type-driven response) did not change over the 12 months after immunization, but the boosting effect was seen in the IgG1 antibody responses but not in the IgG2a antibody responses. After challenge infection, all immunized mice survived with negligibly patent parasitemia. These findings suggest that protective immune responses to MSP119following immunization using oil-based Montanide ISA51 and CpG ODN as an adjuvant are very long-lasting and encourage clinical trials for malaria vaccine development.
- 1 April 2007
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (4) , 342-347
Long-Lasting Protective Immune Response to the 19-Kilodalton Carboxy-Terminal Fragment ofPlasmodium yoeliiMerozoite Surface Protein 1 in Mice
Merozoite surface protein 1 (MSP1) is the major protein on the surface of the plasmodial merozoite, and its carboxy terminus, the 19-kDa fragment (MSP119), is highly conserved and effective in induction of a protective immune response against malaria parasite infection in mice and monkeys. However, the duration of the immune response has not been elucidated. As such, we immunized BALB/c mice with a standard four-dose injection of recombinantPlasmodium yoeliiMSP119formulated with Montanide ISA51 and CpG oligodeoxynucleotide (ODN) and monitored the MSP119-specific antibody levels for up to 12 months. The antibody titers persisted constantly over the period of time without significant waning, in contrast to the antibody levels induced by immunization with Freund's adjuvant, where the antibody levels gradually declined to significantly lower levels 12 months after immunization. Investigation of immunoglobulin G (IgG) subclass longevity revealed that only the IgG1 antibody level (Th2 type-driven response) decreased significantly by 6 months, while the IgG2a antibody level (Th1 type-driven response) did not change over the 12 months after immunization, but the boosting effect was seen in the IgG1 antibody responses but not in the IgG2a antibody responses. After challenge infection, all immunized mice survived with negligibly patent parasitemia. These findings suggest that protective immune responses to MSP119following immunization using oil-based Montanide ISA51 and CpG ODN as an adjuvant are very long-lasting and encourage clinical trials for malaria vaccine development.